For: | Unluturk U, Aksoy S, Yonem O, Bayraktar Y, Tekuzman G. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkın’s lymphoma patient. World J Gastroenterol 2006; 12(12): 1978-1979 [PMID: 16610013 DOI: 10.3748/wjg.v12.i12.1978] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v12/i12/1978.htm |
Number | Citing Articles |
1 |
Matthew Rong Jie Tay, Soon Thye Lim, Miriam Tao, Richard Hong-Hui Quek, Kevin Tay, Thuan Tong Tan. Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy. Leukemia & Lymphoma 2014; 55(1): 182 doi: 10.3109/10428194.2013.798867
|
2 |
Qingling Hua, Yanzhe Zhu, Hu Liu. Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis. Journal of Chemotherapy 2015; 27(6): 365 doi: 10.1179/1973947815Y.0000000025
|
3 |
Hung Chang, Huei-Chung Yeh, Yung-Cheng Su, Ming-Hsun Lee. Pneumocystis jiroveci Pneumonia in Patients with Non-Hodgkin's Lymphoma Receiving Chemotherapy Containing Rituximab. Journal of the Chinese Medical Association 2008; 71(11): 579 doi: 10.1016/S1726-4901(08)70173-4
|
4 |
Sercan Aksoy, Ömer Dizdar, Mutlu Hayran, Hakan Harputluoğlu. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leukemia & Lymphoma 2009; 50(3): 357 doi: 10.1080/10428190902730219
|
5 |
Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. 2010; : 371 doi: 10.1016/B978-0-444-53273-2.50007-9
|
6 |
F.A. Goumas, F. Braun, D.C. Broering, M. Behrend. . Side Effects of Drugs Annual 2009; 31: 589 doi: 10.1016/S0378-6080(09)03137-7
|
7 |
Jason Seewoodhary. Cytomegalovirus enterocolitis in a patient with diffuse large B-cell lymphoma after chemotherapy with rituximab. World Journal of Gastroenterology 2006; 12(45): 7391-7391 doi: 10.3748/wjg.v12.i45.7391
|
8 |
Sercan Aksoy, Hakan Harputluoglu, Saadettin Kilickap, Didem Sener Dede, Omer Dizdar, Kadri Altundag, Ibrahim Barista. Rituximab-related viral infections in lymphoma patients. Leukemia & Lymphoma 2007; 48(7): 1307 doi: 10.1080/10428190701411441
|
9 |
Theodoros Kelesidis, George Daikos, Dimitrios Boumpas, Sotirios Tsiodras. Does rituximab increase the incidence of infectious complications? A narrative review. International Journal of Infectious Diseases 2011; 15(1): e2 doi: 10.1016/j.ijid.2010.03.025
|
10 |
Mitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, Tomoyuki Endo, Toshiya Sakai, Masato Obara, Kohki Kumano, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Norihiro Sato, Kazuki Koizumi, Masaya Mukai, Takao Koike. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non‐Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. British Journal of Haematology 2007; 137(4): 349 doi: 10.1111/j.1365-2141.2007.06584.x
|
11 |
P. Befort, S. Riviere, A. Maran, J. Ramos, A. Lequellec. Perforations digestives itératives secondaires à une cryoglobulinémie essentielle et au cytomégalovirus : à propos d’un cas. La Revue de Médecine Interne 2010; 31(2): 167 doi: 10.1016/j.revmed.2009.03.014
|
12 |
Yuko Kanbayashi, Kenichi Nomura, Yoshiko Fujimoto, Mihoko Yamashita, Muneo Ohshiro, Kousuke Okamoto, Yosuke Matsumoto, Shigeo Horiike, Tatsuya Takagi, Yoji Ishida, Masafumi Taniwaki. Risk factors for infection in haematology patients treated with rituximab. European Journal of Haematology 2009; 82(1): 26 doi: 10.1111/j.1600-0609.2008.01165.x
|
13 |
|